This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why G1 THERAPEUTICS (GTHX) is Poised for a Turnaround After Losing 16.4% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for G1 THERAPEUTICS (GTHX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
G1 THERAPEUTICS (GTHX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
G1 THERAPEUTICS (GTHX) delivered earnings and revenue surprises of 2.08% and 144.77%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate G1 THERAPEUTICS (GTHX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
G1 THERAPEUTICS (GTHX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
G1 THERAPEUTICS (GTHX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
G1 THERAPEUTICS (GTHX) delivered earnings and revenue surprises of 40.37% and 3711.80%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Ocugen (OCGN) is likely to provide update related to regulatory progress of its COVID-19 vaccine, Covaxin, in the United States when it reports first-quarter 2021 results.
How G1 Therapeutics (GTHX) Stock Stands Out in a Strong Industry
by Zacks Equity Research
G1 Therapeutics (GTHX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Company News For Jun 19, 2019
by Zacks Equity Research
Companies In The News Are: BA,GCP,GTHX,PSN
5 Domestic Stocks to Gain From Thaw in Trade Talks
by Zacks Equity Research
The United States and China's outstanding disagreements on a few key issues could delay a favorable deal.
G1 THERAPEUTICS Enters Oversold Territory
by Zacks Equity Research
G1 THERAPEUTICS (GTHX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
G1 Therapeutics (GTHX) in Focus: Stock Moves 8.9% Higher
by Zacks Equity Research
Shares of G1 Therapeutics (GTHX) rose nearly 9% yesterday.